Abstract:Abstract Background Interleukin-33 (IL-33) is an effective inducer of pro-inflammatory cytokines regulating innate and adaptive immunity. Inflammation could be a double-edged sword, promoting or inhibiting tumour growth. To date, the roles and mechanisms of IL-33 in tumours remain controversial. Here, we examined the effect of exogenous IL-33 on the biological characteristics of hepatocellular carcinoma (HCC) and the possible mechanism of action. Methods In this study, IL-33 expression in the tissues of 69 HCC patients was detected and its relationship with prognosis was evaluated. After establishing a mouse HCC model and IL-33 treatment operation, the infiltration of splenic myeloid-derived suppressor (MDSCs), dendritic (DCs), regulatory T, and natural killer (NK) cells was detected by flow cytometry analysis, and the vascular density of the tumour tissues was detected by immunohistochemistry to reveal the mechanism of IL-33 in HCC proliferation. Finally, the Cancer Genome Atlas database was used to analyse Gene Ontology terms the and Kyoto Encyclopaedia of Genes and Genomes pathway. Moreover, the chi-square test, two-tailed unpaired Student’s t -test, and multiple t- tests were performed using SPSS version 23.0 and GraphPad Prism 8.0 software. Results The IL-33 expression level was negatively correlated with the overall survival of HCC patients, suggesting its potential clinical significance in the prognosis of HCC. We found that systemic IL-33 administration significantly promoted the tumour size in vivo. Furthermore, the IL-33-treated mice presented decreased frequencies of tumouricidal NK and CD69 + CD8 + T cells. After IL-33 treatment, the incidence of monocytic MDSCs and conventional DCs increased, while that of granulocytic MDSCs decreased. Moreover, IL-33 promoted the formation of intracellular neovascularization. Therefore, IL-33 accelerated HCC progression by increasing the accumulation of immunosuppressive cells and neovascularization formation. Finally, we found that the transcription of IL-33 was closely related to the PI3K-Akt and MAPK pathways in Gene Set Enrichment Analysis plots, which were involved in the tumourigenesis and pathogenesis of HCC. Conclusions Taken together, IL-33 may be a key tumour promoter of HCC proliferation and tumourigenicity, an important mediator, and a potential therapeutic target for regulating HCC progression.

IL-33 Drives the Antitumour Effects of Dendritic Cells Via Upregulating CYLD Expression in Pulmonary Adenocarcinoma.

CYLD Expression in Dendritic Cells Involved in the Immunoregulation of Pulmonary Adenocarcinoma Via NF-κB Pathway.

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy

IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice

Cmar_a_262745 7527..7537

The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.

Interleukin‐33 Activates and Recruits Natural Killer Cells to Inhibit Pulmonary Metastatic Cancer Development

Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer

Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment

Abstract 2700: Therapeutic IL-33 enhances the antigen presentation function of ILC2s to exert anti-tumor immune activity

IL-33 immunohistochemical pattern of expression in neoplastic and nonneoplastic peripheral lung tissues of stage 1 o 2 lung adenocarcinoma

IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma

IL-33 amplifies airways inflammation in a murine surrogate of asthma possibly through acting on dendritic cells

The Controversial Role of IL-33 in Lung Cancer

Relationship and prognostic significance of IL‐33, PD‐1/PD‐L1, and tertiary lymphoid structures in cervical cancer

[Assessment of baseline CCL19+ dendritic cell infiltration for predicting responses to immunotherapy in lung adenocarcinoma patients]

IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4+ and CD8+ T Cell Responses in Hepatocellular Carcinoma

IL-33 and IL-33-derived DC-based tumor immunotherapy

Th22 Cells/IL-22 Serves as a Protumor Regulator to Drive Poor Prognosis through the JAK-STAT3/MAPK/AKT Signaling Pathway in Non-Small-Cell Lung Cancer

Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression